Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Influenza A H3N2 Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations

NCT01746082
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H3N2 variant Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
4
States / cities
Decatur, Georgia • Iowa City, Iowa • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Jul 23, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

NCT01498718
View directory record Official record
Conditions
Influenza
Interventions
DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Jul 23, 2026, 9:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

NCT01246999
View directory record Official record
Conditions
Influenza
Interventions
Live attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV, LAIV followed by TIV
Biological
Lead sponsor
University of Rochester
Other
Eligibility
2 Years to 9 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Jul 23, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

NCT06087640
View directory record Official record
Conditions
Influenza, Human
Interventions
aQIV or aTIV, QIV or TIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
65 Years and older
Enrollment
38,769 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
111
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 23, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

NCT04978454
View directory record Official record
Conditions
Influenza
Interventions
Influenza RG-A/Texas/71/2017 (H3N2) Challenge, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Jul 23, 2026, 9:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults

NCT03743688
View directory record Official record
Conditions
Influenza, Influenza, Human, Vaccine Reaction, Influenza A, Influenza Type B, Influenza A H1N1, Influenza A H3N2
Interventions
Influenza Vaccine Recipients
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 4, 2019 · Synced Jul 23, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

NCT04785794
View directory record Official record
Conditions
Influenza Vaccine
Interventions
Sing2016 M2SR H3N2 influenza vaccine, Placebo
Biological · Other
Lead sponsor
FluGen Inc
Industry
Eligibility
50 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 23, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations

NCT02100436
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
8
States / cities
Atlanta, Georgia • Baltimore, Maryland • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Jul 23, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

H3N2 M2SR in Pediatric Population

NCT03553940
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine, Placebo, Quadrivalent MDCK Inactivated Influenza Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
9 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Jul 23, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Texas 2017 (H3N2) Challenge Study

NCT06476275
View directory record Official record
Conditions
Influenza Viral Infections
Interventions
Influenza A/Texas/71/2017 (H3N2), Sham placebo
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 46 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Jul 23, 2026, 9:34 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Pilot Influenza Challenge Study

NCT07063849
View directory record Official record
Conditions
Influenza
Interventions
A/Texas
Biological
Lead sponsor
Daniel Hoft, MD, PhD
Other
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jul 23, 2026, 9:34 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine

NCT04960397
View directory record Official record
Conditions
H3N2 Influenza
Interventions
Placebo, Sing2016 M2SR H3N2
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Iowa City, Iowa • Baltimore, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Jul 23, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers

NCT02822105
View directory record Official record
Conditions
Flu
Interventions
the H3N2 M2SR monovalent influenza vaccine, Placebo
Biological · Other
Lead sponsor
FluGen Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Jul 23, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

NCT03999554
View directory record Official record
Conditions
Influenza A
Interventions
LD Sing2016 M2SR H3N2 influenza vaccine, MD Sing2016 M2SR H3N2 influenza vaccine, HD Sing2016 M2SR H3N2 influenza vaccine, LD Bris10 M2SR H3N2 influenza vaccine, Placebo
Biological · Other
Lead sponsor
FluGen Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
Hollywood, Florida • Lenexa, Kansas • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jul 23, 2026, 9:34 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A/Texas Flu Challenge

NCT06753474
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus influenza A H3N2 strain
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 23, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults

NCT05163847
View directory record Official record
Conditions
Influenza Vaccine
Interventions
Cam2020 M2SR H3N2 influenza vaccine, Fluzone HD IIV, IN Placebo, IM Placebo
Biological · Other
Lead sponsor
FluGen Inc
Industry
Eligibility
65 Years to 85 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
6
States / cities
Port Orange, Florida • Meridian, Idaho • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Jul 23, 2026, 9:34 PM EDT
Completed Phase 1 Interventional

Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers

NCT02594189
View directory record Official record
Conditions
Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2
Interventions
Live recombinantly derived A/Bethesda/MM1/H3N2 virus
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Jul 23, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

NCT03315104
View directory record Official record
Conditions
Influenza A H3N2, Influenza A H1N1
Interventions
FLU-IGIV, Placebo for FLU-IGIV
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Jul 23, 2026, 9:34 PM EDT